LOY-003: IGF-1-lowering daily pill for large breed dogs (Loyal)
LOY-003 is Loyal's daily pill counterpart to LOY-001, intended for large breed dogs aged 5 years or older weighing at least 60 lb and targeting IGF-1 over-expression. The company reports that its reasonable-expectation-of-effectiveness section was completed in 2026. No trial design or results have been published.
Record
| Design | company regulatory program |
|---|---|
| Status | ongoing |
| Intervention | LOY-003, a prescription daily pill targeting IGF-1 over-expression |
| Intervention class | drug |
| Dose regimen | daily oral tablet (dose not disclosed) |
| Breed | large breeds |
| Age | 5 years and older, weighing at least 60 lb |
| Primary outcome | healthy lifespan extension |
| Lead organisation | Loyal (San Francisco) |
| Sponsor or funder | Loyal |
| Tags | lifespan, drug, igf-1, large-breeds, fda-conditional-approval, loyal |
Notes: Company- and press-sourced only; developed with Crinetics Pharmaceuticals according to the company; trial details undisclosed as of 2026-10-01.
Sources and verbatim quotes
Loyal: for dog owners (company page) (2026), snapshot loyal-for-dog-owners (company)
LOY-001 is a prescription long-acting injection, while LOY-003 is a prescription daily pill.
LOY-001 is intended for dogs 7 years and older, weighing at least 40 lb, whereas LOY-003 is developed for dogs 5 years and older, weighing at least 60 lb.
In 2026, LOY-003 completed its RXE section.
Loyal drug LOY-001 to extend lifespan of giant dog breeds (Gizmodo) (2023), snapshot gizmodo-loy-001 (press)
Loyal is also developing a pill that would address the same issue, codenamed LOY-003.
Reproduce: canine_trial_search(trial_id="loyal-loy-003-large-dogs-pill") in dog-geroscience-mcp; dataset canine-trial-registry.